More reads
- Axsome’s depression drug succeeds in late-stage trial. (STAT Plus)
- Lawmakers say a Lilly program to offer half-price insulin is a bust. (STAT Plus)
- Wave Life Sciences crashes on negative outcome of Duchenne muscular dystrophy study. (STAT)
- A controversial dwarfism drug, after clearing pivotal study, heads to the FDA. (STAT)
.png)
No hay comentarios:
Publicar un comentario